UA117779C2 - Піразини як модулятори gpr6 - Google Patents

Піразини як модулятори gpr6

Info

Publication number
UA117779C2
UA117779C2 UAA201609102A UAA201609102A UA117779C2 UA 117779 C2 UA117779 C2 UA 117779C2 UA A201609102 A UAA201609102 A UA A201609102A UA A201609102 A UAA201609102 A UA A201609102A UA 117779 C2 UA117779 C2 UA 117779C2
Authority
UA
Ukraine
Prior art keywords
gpr6
modulators
pyrazines
compounds
intermediates
Prior art date
Application number
UAA201609102A
Other languages
English (en)
Inventor
Марк Е. АДАМС
Джейсон У. Браун
Стівен Хічкок
Марія Хопкінс
Сьота Кікучі
Бетті Лем
Хольгер Моненшейн
Холлі Рейхард
Хуейкай Сунь
Original Assignee
Такеда Фармасьютікал Компані Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютікал Компані Лімітед filed Critical Такеда Фармасьютікал Компані Лімітед
Publication of UA117779C2 publication Critical patent/UA117779C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Даний винахід пропонує сполуки формули (І): , (I) які придатні як модулятори GPR6, їх фармацевтичну композицію, способи лікування станів, пов'язаних з GPR6, способи одержання сполук і їх проміжних сполук.
UAA201609102A 2014-02-14 2015-02-13 Піразини як модулятори gpr6 UA117779C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461940294P 2014-02-14 2014-02-14
PCT/US2015/015841 WO2015123533A1 (en) 2014-02-14 2015-02-13 Pyrazines modulators of gpr6

Publications (1)

Publication Number Publication Date
UA117779C2 true UA117779C2 (uk) 2018-09-25

Family

ID=52598823

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201609102A UA117779C2 (uk) 2014-02-14 2015-02-13 Піразини як модулятори gpr6

Country Status (24)

Country Link
US (2) US10000468B2 (uk)
EP (1) EP3105216B1 (uk)
JP (1) JP6484640B2 (uk)
KR (1) KR20160122215A (uk)
CN (1) CN106103421B (uk)
AU (1) AU2015218402B2 (uk)
BR (1) BR112016018418A2 (uk)
CA (1) CA2939382A1 (uk)
CL (1) CL2016002043A1 (uk)
CR (1) CR20160428A (uk)
DO (1) DOP2016000211A (uk)
EA (1) EA033861B1 (uk)
EC (1) ECSP16074207A (uk)
ES (1) ES2702205T3 (uk)
GE (1) GEP20186893B (uk)
IL (1) IL247140B (uk)
MA (1) MA39337B1 (uk)
MX (1) MX369857B (uk)
MY (1) MY184366A (uk)
PE (1) PE20170245A1 (uk)
PH (1) PH12016501613B1 (uk)
UA (1) UA117779C2 (uk)
WO (1) WO2015123533A1 (uk)
ZA (1) ZA201606077B (uk)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160428A (es) * 2014-02-14 2017-04-04 Takeda Pharmaceuticals Co Pizazinas moduladoras de gpr6
KR20230109185A (ko) 2016-06-07 2023-07-19 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
JP6878615B2 (ja) 2017-03-23 2021-05-26 ジャコバイオ ファーマスーティカルズ カンパニー リミテッドＪａｃｏｂｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． Ｓｈｐ２阻害剤として有用な新規な複素環式誘導体
WO2018183145A1 (en) * 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
JOP20180057A1 (ar) * 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
US5563142A (en) * 1989-12-28 1996-10-08 The Upjohn Company Diaromatic substituted compounds as anti-HIV-1 agents
JP2004515449A (ja) * 1999-02-26 2004-05-27 アリーナ・フアーマシユーチカルズ・インコーポレーテツド 第６ｇタンパク質共役型受容体の小分子調節物質
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
EE200200453A (et) 2000-02-16 2003-12-15 Neurogen Corporation Asendatud arüülpürasiinid
DK1397351T3 (da) * 2001-06-01 2010-01-18 Hoffmann La Roche Pyrimidin-, triazin- og pyrazinderivater som glutamatreceptorer
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
NZ534830A (en) 2002-03-13 2005-08-26 Janssen Pharmaceutica Nv Compounds with histone deacetylase HDAC inhibiting activity and oral bioavailability useful for treating proliferative diseases
WO2004054617A1 (ja) 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. 中枢疾患の予防および／または治療剤
SG145701A1 (en) 2003-07-30 2008-09-29 Xenon Pharmaceuticals Inc Piperazine derivatives and their use as therapeutic agents
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050070718A1 (en) * 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20070149547A1 (en) 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
AU2005252160A1 (en) 2004-04-13 2005-12-22 Astellas Pharma Inc. Polycyclic pyrazines as potassium ion channel modulators
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
US20060258672A1 (en) 2005-05-13 2006-11-16 Joseph Barbosa Multicyclic compounds and methods of their use
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
US8495335B2 (en) * 2006-06-16 2013-07-23 Raytheon Company Data translation system and method
EP2303859A4 (en) 2008-06-20 2012-08-22 Metabolex Inc ARYL GPR119 AGONISTS AND USES THEREOF
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
MX2012013127A (es) 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
AU2011253057B2 (en) * 2010-05-13 2014-11-20 Amgen Inc. Nitrogen heterocyclic compounds useful as PDE10 inhibitors
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
WO2013063458A2 (en) * 2011-10-27 2013-05-02 Mayo Foundation For Medical Education And Research Inhibiting g protein coupled receptor 6 kinase polypeptides
US9487526B2 (en) * 2012-08-13 2016-11-08 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as GPR6 modulators
SG11201602387RA (en) 2013-10-21 2016-05-30 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
CR20160428A (es) * 2014-02-14 2017-04-04 Takeda Pharmaceuticals Co Pizazinas moduladoras de gpr6

Also Published As

Publication number Publication date
ES2702205T3 (es) 2019-02-27
CR20160428A (es) 2017-04-04
BR112016018418A2 (pt) 2017-08-08
EP3105216B1 (en) 2018-10-10
PE20170245A1 (es) 2017-03-30
EA033861B1 (ru) 2019-12-03
GEP20186893B (en) 2018-09-10
JP2017509601A (ja) 2017-04-06
ZA201606077B (en) 2018-11-28
KR20160122215A (ko) 2016-10-21
IL247140A0 (en) 2016-09-29
MX369857B (es) 2019-11-25
EP3105216A1 (en) 2016-12-21
AU2015218402A1 (en) 2016-09-15
MX2016010529A (es) 2016-10-31
ECSP16074207A (es) 2017-09-29
US20170174659A1 (en) 2017-06-22
MA39337B1 (fr) 2019-11-29
MA39337A1 (fr) 2017-10-31
IL247140B (en) 2020-02-27
WO2015123533A1 (en) 2015-08-20
CA2939382A1 (en) 2015-08-20
US10273225B2 (en) 2019-04-30
CN106103421B (zh) 2019-04-09
US10000468B2 (en) 2018-06-19
JP6484640B2 (ja) 2019-03-13
AU2015218402B2 (en) 2019-07-11
MY184366A (en) 2021-04-01
EA201691632A1 (ru) 2017-02-28
PH12016501613A1 (en) 2017-02-06
US20180258073A1 (en) 2018-09-13
CL2016002043A1 (es) 2017-02-17
DOP2016000211A (es) 2016-10-16
PH12016501613B1 (en) 2017-02-06
CN106103421A (zh) 2016-11-09

Similar Documents

Publication Publication Date Title
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
PH12018500457A1 (en) New phenoxymethyl derivatives
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
PH12017500660A1 (en) Novel compositions, uses and methods for making them
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
PH12017500920A1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazine as modulators of gpr139
EP3795578A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
PH12016501613B1 (en) Pyrazines modulators of gpr6
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2018011877A (es) Proceso mejorado para la preparacion de tartrato de butorfanol.
IN2014CH00840A (uk)
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
MX2019002017A (es) Derivados de sofosbuvir para el tratamiento de la hepatitis c.
MX2019008375A (es) Tiobenzoimidazol como fungicidas.
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
SG10201803880TA (en) Stable compositions of neuroactive peptides
PH12017501147A1 (en) Total synthesis of trioxacarcin dc-45-a2 and preparation of trioxacarcin analogs
IN2014MU00197A (uk)
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
IN2014MU00069A (uk)
IN2013MU01524A (uk)